Drugs / Human T Lymphoid Progenitor
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04707300 | Feb 2022 → Nov 2026 expected | hematopoietic and lymphoid cell neoplasm | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03879876 | May 2020 → Sep 2023 | disease related to hematopoietic stem cell transplant, severe combined immunodeficiency | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human T Lymphoid Progenitor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04707300 ↗ |
| Known as | HTLP | “Human T Lymphoid Progenitor (HTLP) injection” NCT04707300 ↗1“Human T Lymphoid Progenitor (HTLP) injection” NCT03879876 ↗ |
| Modality | Cell therapy | “HTLP cellular product obtained after 7 days of culture of immune-selected CB” NCT04707300 ↗ |
| Route | Intravenous | “will be injected intravenously” NCT04707300 ↗ |